Clearmind Medicine (CSE: CMND), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced that Mark Haden has joined its scientific advisory board (“SAB”). The SAB’s initial focus will be providing guidance on the company’s request for an Investigational New Drug … Continue reading InvestorNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) Announces Board Appointment of Psychedelic Medicine Expert